Hoth Therapeutics rises as skin treatment shows promise in cancer patients

Shares of biotech firm Hoth Therapeutics HOTH.O rise ~7% to around $0.07

Co says its experimental topical drug HT-001 helped ease skin problems caused by EGFR cancer therapy, a treatment that often leads to rashes and irritation

EGFR therapy is a common cancer treatment that blocks signals helping tumors grow, but it can damage healthy skin, affecting patients’ quality of life - HOTH

Co says repeated use of HT-001 increased local drug exposure by about 77%, while absorption into the bloodstream stayed very low, below 0.5% of oral drugs

Says no serious side effects were reported and no patients stopped treatment due to safety issues

Shares rose ~32% in 2025